Orbem Raises €55.5M to Revolutionize Food and Biological Systems Analysis with AI-Powered MRI

Orbem, a Munich-based deeptech company, has secured a significant €55.5 million Series B financing round to scale its innovative AI-powered MRI technology. This investment, led by Innovation Industries, with participation from Supernova Invest and follow-on investments from existing backers, signals a major leap forward in the application of artificial intelligence to industrialize magnetic resonance imaging. Orbem's technology has the potential to transform various sectors, including agriculture, food production, and health, by providing fast, scalable, and non-invasive analysis of biological materials.



The company's platform generates actionable insights from biological data, supporting decision-making across these industries. One of the most compelling applications of Orbem's technology is in the poultry industry, where its flagship product, Genus Focus, uses AI-enabled MRI to determine the sex of a poultry egg non-invasively in under one second. This innovation provides an alternative to the culling of male chicks, a practice restricted in parts of the European Union. To date, the system has been used to scan more than 170 million eggs, demonstrating its potential for widespread adoption.



The implications extend beyond the poultry industry. Orbem's technology can evaluate seed viability, assess produce quality without destructive testing, and even determine embryo sex in eggs. These capabilities can significantly improve efficiency, reduce waste, and increase transparency across biological value chains. The Series B funding will support Orbem's expansion into the United States, further scaling of its poultry solutions, and entry into the fruit and vegetable sector using non-destructive quality analysis. Additionally, the company will continue developing healthcare applications based on large-scale biological data, opening up new avenues for medical research and diagnosis.



For everyday users, this could mean having access to higher quality, more sustainably produced food. From an industry perspective, Orbem's technology could reshape how companies approach food production, from farming to distribution, by providing them with tools to make more informed decisions. This shift could also have broader societal effects, such as reducing waste and promoting more ethical farming practices.



Orbem's success and the significant investment it has attracted underscore the growing importance of AI in transforming traditional industries. As technology continues to advance, we can expect to see more innovative applications of AI in sectors that were previously untouched by digital transformation. The potential for AI-powered MRI technology to improve our understanding and management of biological systems is vast, and Orbem is at the forefront of this revolution.



The company's ability to secure such a substantial investment is a testament to the viability of its technology and the market's belief in its potential. With this funding, Orbem is poised to make a significant impact on a global scale, from improving food production efficiency to advancing healthcare through the analysis of biological data. As the world becomes increasingly aware of the need for sustainable and efficient practices, innovations like Orbem's AI-powered MRI technology will play a crucial role in shaping the future of various industries.



In conclusion, Orbem's €55.5 million Series B funding round is not just a financial milestone; it represents a major step forward in the application of AI to real-world problems. The potential of Orbem's technology to transform industries and improve lives is undeniable, and its journey is one that will be closely watched by both the tech and the agricultural communities.